Works cited by this work
213 works
Work: Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology
Polymeric Nanoparticles for Drug Delivery
Maximilian A. Beach, Umeka Nayanathara, Yanting Gao +4
Review article20247 citationsABIIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25
Article20215 citationsABICAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu, Changhai Lei, Shuowu Liu +12
Article20194 citationsABITargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6
Article20174 citationsABIThe paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials
Vahid Moradi, Azadeh Omidkhoda, Naser Ahmadbeigi
Review article20234 citationsABIProgress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review
Vahid Moradi, Elnaz Khodabandehloo, Mehdi Alidadi +2
Review article20244 citationsABIPhase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang, Na Li, Kaichao Feng +14
Article20213 citationsABITisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21
Article20183 citationsABITGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
Na Tang, Chen Cheng, Xingying Zhang +6
Article20203 citationsABITisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32
Article20183 citationsABICurrent hurdles to the translation of nanomedicines from bench to the clinic
Snežana Đorđević, María Medel Gonzalez, Inmaculada Conejos‐Sánchez +6
Review article20213 citationsABIRecent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery
Jialiang Wang, Yaopeng Ding, K. Chul Chong +7
Review article20243 citationsABIFrom ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
Eleonora Pinto, Lisa A. Lione, Mirco Compagnone +8
Review article20253 citationsABISide-effect management of chimeric antigen receptor (CAR) T-cell therapy
Maria‐Luisa Schubert, Michael Schmitt, L. Wang +4
Review article20202 citationsABILipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Jinge Zhou, Lei Sun, Yujie Jia +8
Article20222 citationsABIOvercoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute +4
Review article20222 citationsABICAR-T cell-derived exosomes: a new perspective for cancer therapy
Farnaz Sani, Shabnam Shojaei, Seyed Amirhossein Tabatabaei +4
Review article20242 citationsABI